Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma

References

• MotzerRJ, HutsonTE, TomczakP, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–124. doi:10.1056/NEJMoa06504417215529
   PubMed Web of Science ®Google Scholar
• MotzerRJ, JonaschE, MichaelsonMD, et al. NCCN guidelines insights: kidney cancer, version 2.2020. J Natl Compr Canc Netw. 2019;17(11):1278–1285. doi:10.6004/jnccn.2019.005431693980
   PubMed Web of Science ®Google Scholar
• LiXS, WuX, ZhaoPJ, et al. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma. Chin Med J. 2011;124(18):2920–2924.22040503
   PubMed Web of Science ®Google Scholar
• KimHS, HongMH, KimK, et al. Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. Oncology. 2011;80(5–6):395–405. doi:10.1159/00033036121829041
   PubMed Web of Science ®Google Scholar
• YooC, KimJE, LeeJL, et al. The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn J Clin Oncol. 2010;40(10):980–985. doi:10.1093/jjco/hyq07320457723
   PubMed Web of Science ®Google Scholar
• MotzerRJ, HutsonTE, TomczakP, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584–3590. doi:10.1200/JCO.2008.20.129319487381
   PubMed Web of Science ®Google Scholar
• HoukBE, BelloCL, KangD, AmanteaM. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res. 2009;15(7):2497–2506. doi:10.1158/1078-0432.CCR-08-189319258444
   PubMed Web of Science ®Google Scholar
• MotzerRJ, HutsonTE, OlsenMR, et al. Randomized Phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol. 2012;30(12):1371–1377. doi:10.1200/JCO.2011.36.413322430274
   PubMed Web of Science ®Google Scholar
• BjarnasonGA, KnoxJJ, KollmannsbergerCK, et al. The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: a phase 2 clinical trial. Eur J Cancer. 2019;108:69–77. doi:10.1016/j.ejca.2018.12.00630648632
   PubMed Web of Science ®Google Scholar
• SabanathanD, ZhangA, FoxP, et al. Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring. Cancer Chemother Pharmacol. 2017;80(2):385–393. doi:10.1007/s00280-017-3362-128667354
   PubMed Web of Science ®Google Scholar
• CabelL, BlanchetB, Thomas-SchoemannA, et al. Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study. Fundam Clin Pharmacol. 2018;32(1):98–107. doi:10.1111/fcp.1232729055166
   PubMed Web of Science ®Google Scholar
• TakasakiS, KawasakiY, KikuchiM, et al. Relationships between sunitinib plasma concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma. Int J Clin Oncol. 2018;23(5):936–943. doi:10.1007/s10147-018-1302-729860539
   PubMed Web of Science ®Google Scholar
• NumakuraK, FujiyamaN, TakahashiM, et al. Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients. Oncotarget. 2018;9(38):25277–25284. doi:10.18632/oncotarget.2542329861870
   PubMedGoogle Scholar
• EisenhauerEA, TherasseP, BogaertsJ, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.02619097774
   PubMed Web of Science ®Google Scholar
• GoodmanVL, RockEP, DagherR, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res. 2007;13(5):1367–1373. doi:10.1158/1078-0432.CCR-06-232817332278
   PubMed Web of Science ®Google Scholar
• (U.S) NCI. Common Terminology Criteria for Adverse Events V4.0. Bethesda, MD: U.S Dept of Health and Human Services, National Institutes of Health, National Cancer Institute; 2009.
   Google Scholar
• ZhangX, SunG, ZhaoJ, et al. Improved long-term clinical outcomes and safety profile of sunitinib dosing schedule with 4/2 switched To 2/1 in patients with metastatic renal cell carcinoma. J Cancer. 2018;9(18):3303–3310. doi:10.7150/jca.2569330271490
   PubMed Web of Science ®Google Scholar
• MendelDB, LairdAD, XinX, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327–337.12538485
   PubMed Web of Science ®Google Scholar
• KhosravanR, MotzerRJ, FumagalliE, RiniBI. Population pharmacokinetic/pharmacodynamic modeling of sunitinib by dosing schedule in patients with advanced renal cell carcinoma or gastrointestinal stromal tumor. Clin Pharmacokinet. 2016;55(10):1251–1269. doi:10.1007/s40262-016-0404-527154065
   PubMed Web of Science ®Google Scholar
• FaivreS, DelbaldoC, VeraK, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24(1):25–35. doi:10.1200/JCO.2005.02.219416314617
   PubMed Web of Science ®Google Scholar